NCT01525212View on ClinicalTrials.gov

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Chronic Hepatitis C
Interventions
DRUG

BMS-929075

Oral Suspension, ≤ 25 mg, Once daily, 3 days

DRUG

BMS-929075

Oral Suspension, ≤ 100 mg, Once daily, 3 days

DRUG

BMS-929075

Oral Suspension, ≤ 400 mg, Once daily, 3 days

DRUG

BMS-929075

Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days

DRUG

Placebo matching BMS-929075

Oral Suspension, 0 mg, Once daily, 3 days

DRUG

Placebo matching BMS-929075

Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days

Trial Locations (3)

3004

Local Institution, Melbourne

4006

Local Institution, Herston

5000

Local Institution, Adelaide

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY